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Abstract
Background: Sporadic late-onset Alzheimer’s disease (AD) appears to evolve from an interplay between genetic
and environmental factors. One environmental factor that continues to be of great interest is that of Chlamydia
pneumoniae infection and its association with late-onset disease. Detection of this organism in clinical and autopsy
samples has proved challenging using a variety of molecular and histological techniques. Our current investigation
utilized immunohistochemistry with a battery of commercially available anti-C. pneumoniae antibodies to determine
whether C. pneumoniae was present in areas typically associated with AD neuropathology from 5 AD and 5 non-
AD control brains.
Results: Immunoreactivity for C. pneumoniae antigens was observed both intracellularly in neurons, neuroglia,
endothelial cells, and peri-endothelial cells, and extracellularly in the frontal and temporal cortices of the AD brain
with multiple C. pneumoniae-specific antibodies. This immunoreactivity was seen in regions of amyloid deposition
as revealed by immunolabeling with two different anti-beta amyloid antibodies. Thioflavin S staining, overlaid with
C. pneumoniae immunolabeling, demonstrated no direct co-localization of the organism and amyloid plaques.
Further, the specificity of C. pneumoniae labeling of AD brain sections was demonstrated using C. pneumoniae
antibodies pre-absorbed against amyloid b 1-40 and 1-42 peptides.
Conclusions: Anti-C. pneumoniae antibodies, obtained commercially, identified both typical intracellular and
atypical extracellular C. pneumoniae antigens in frontal and temporal cortices of the AD brain. C. pneumoniae,
amyloid deposits, and neurofibrillary tangles were present in the same regions of the brain in apposition to one
another. Although additional studies are required to conclusively characterize the nature of Chlamydial
immunoreactivity in the AD brain, these results further implicate C. pneumoniae infection with the pathogenesis of
Alzheimer’s disease.
Background
Alzheimer’sd i s e a s e( A D )i sap r o g ressive neurological
disease that affects millions of older individuals. Distinc-
tive pathological hallmarks associated with the disease
include tau accumulations forming neuropil threads
(NTs) and neurofibrillary tangles (NFTs), and deposits of
extracellular amyloid comprising neuritic senile plaques
(NSPs). In general, there are two distinct forms of Alzhei-
mer’s disease, familial AD and sporadic late-onset AD.
The early onset form of the disease, known commonly as
familial AD, is caused by dysregulation of many processes
due to genetic mutations that lead to the aforementioned
pathology. For example, mutations in presenilins 1 and
2 genes and the gene responsible for amyloid-b protein
precursor (AbPP) result in an increased accumulation of
beta-amyloid (Ab) in the brain. In late-onset sporadic
AD, similar pathological accumulations occur, although
without the gene mutations seen in familial AD (for
review see Duyckaerts 2009) [1].
Most investigations have focused on the extracellular,
deposited forms of amyloid in the AD brain. The extra-
cellular accumulations of amyloid in the brain are com-
posed principally of amyloid b 1-40 and 1-42 and form
neuritic senile plaques (NSP) [1,2]. However, intracellu-
lar accumulations of amyloid, which may occur prior to
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[3-6]. Further, Ab-derived diffusible ligands (ADDLs),
soluble forms of amyloid, have been postulated to be a
toxic form of amyloid at the synapses and are not found
in typical neuropathological or histopathologic accumu-
lations of amyloid [7]. Since late-onset AD lacks the
same mutations seen in familial AD, determination of
the cause of amyloid pathology in late-onset AD
remains poorly understood.
The interplay between normal processes and environ-
mental factors, both independently and in concert with
other genetic factors, may lead to late-onset AD. In par-
ticular, infections as environmental factors may have an
impact on the delicate amyloid and tau balance in the
brain and lead to the pathology seen in AD. A number
of infectious agents have been associated with late-onset
AD [8-12]. Our focus has been on the obligate, intracel-
lular bacterium Chlamydia pneumoniae, which has been
demonstrated to be highly prevalent in the AD brain
[8,12], as well as associated with other systemic and
neurological diseases [13,14]including atherosclerosis
[15,16], stroke [17], encephalitis [18], and multiple
sclerosis [19].
Various cell types found in the brain have been shown
to be susceptible to infection by C. pneumoniae including
endothelia, astroglia, microglia, and neurons [8,12,20-23].
Once inside the cell, C. pneumoniae reside in an intracel-
lular inclusion that resists lysosomal fusion and immune
recognition. C. pneumoniae developmentally cycle from
the infectious elementary body (EBs) to the metabolically
active reticulate body (RBs), which divide by binary
fission. This obligate intracellular pathogen both interacts
with and manipulates the host by gathering energy and
nutrients that are required for replication, such as sphin-
gomyelin and cholesterol [24-26]. Chlamydiae also inhibit
apoptosis [20,27-29] and release factors such as chlamy-
dial lipopolysaccharide (LPS) and glycolipid protein into
both the cell itself and into the surrounding milieu [30].
Further propagation and spread of the organism may
follow one or more pathways. The infectious progeny,
EBs, may be released upon eventual cell death or by
extrusion from the cell in a membrane bound package
into the surrounding environment [31]. Thus, C. pneu-
moniae and/or antigens derived from the organism may
be localized both intracellularly and extracellularly at the
site of infection.
D u et ot h ec h r o n i cn a t u r eo fA Da n dt h ec o m p l e x i t y
of C. pneumoniae infections, establishing an association
with disease pathogenesis has proved difficult. Validating
this association relies on a variety of detection methods
for the organism. Our current study focuses on the use
of immunohistochemistry (IHC) with a battery of com-
mercially available anti-chlamydia antibodies on frontal
and temporal cortical sections of human AD brains.
Our data suggest this methodology provides a valuable
insight into the interrelationship between infection and
AD pathology.
Results
C. pneumoniae immunolabeling in AD tissue
All available sections from the frontal and temporal
cortices of AD and control brains were immunolabeled
with anti-C. pneumoniae antibodies listed in table 1. All
AD brains were found to immunolabel with all of the
anti-C. pneumoniae antibodies, although the type of
labeling profile (eg, intracellular versus extracellular) and
extent of label differed. Representative labeling profiles
were highlighted in Figure 1. An AD brain immunola-
beled with no primary antibody and both an anti-mouse
horseradish peroxidase (HRP) conjugated secondary and
an anti-mouse alkaline phosphatase (AP) conjugated sec-
ondary reacted with both 3, 3′-Diaminobenzidine (DAB)
and AP red illustrate the absence of non specific immu-
nolabeling in the temporal cortex. The AD frontal cortex
labelled with a mouse anti-C. pneumoniae monoclonal
antibody (Table 1, #5) demonstrated both neuropil
(Figure 1B) and intracellular (Figure 1C, D) immunola-
beling. C. pneumoniae was present in the hippocampus
and entorhinal cortex of Alzheimer’sd i s e a s eb r a i n
(Figure 2). Representative immunolabeling with an anti-
C. pneumoniae monoclonal antibody (Table 1, #5) was
observed in the dentate gyrus of the hippocampus indi-
cated by the magenta color (Figure 2A, B). C. pneumo-
niae immunolabeling also was observed in apparent large
neurons within the entorhinal cortex (Figure 2C, D) that
also contained intraneuronal lipofuscin accumulations
(golden brown, arrowheads). Although the chlamydia
immunoreactivity was detected using all anti-chlamydia
antibodies in all AD brains, the extent of the label varied
with the antibody used and AD case examined. Chlamy-
dia immunolabeling was detected in the frontal and
temporal cortices and appeared distributed across all 6
cortical layers. Although the immunolabeling may appear
robust in some areas, in general, the intracellular immu-
noreactivity was observed in less than 1% of brain cells in
Table 1 Commercially available Chlamydia antibodies
1 BioDesign, Meridian Life
Sciences
B65256R Polyclonal 1:100
2 BioDesign, Meridian Life
Sciences
C65165M Monoclonal 1:100
3 BioDesign, Meridian Life
Sciences
C65691M Monoclonal 1:100
4 Fitzgerald 10-C27 Monoclonal 1:100
5 GenWay Biotech 20-902-
170121
Monoclonal 1:100
6 GenWay Biotech 20-272-
190984
Monoclonal 1:100
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Page 2 of 12these regions. The cell types in the grey matter within the
hippocampal formation (Figure 2E) that were labeled
intracellularly include neuroglia, large and small neurons,
pyramidal neurons, although less commonly, and peri-
vascular cells. Similar cell types showed immunoreactiv-
ity across all frontal and temporal cortical layers. This
intracellular immunoreactivity was occasionally seen in
cells with granulovacuolar degeneration and tangles in
these regions. Additionally, the more atypical extracellu-
lar chlamydia immunoreactivity was visualized across all
cortical layers with approximately 1-2% of the area in a
chlamydia-positive field demonstrating immunoreactivity.
This varies widely with different AD cases. Further, the
immunoreactivity was seen in the white matter and even
the cerebellum although study of this immunolabeling
was outside the scope of this report. Minimal immuno-
reactivity was seen in the 2 of 5 non AD cases in the
frontal and temporal regions, not confined to any specific
layer; and there was some hippocampal involvement.
Amyloid and C. pneumoniae immunolabeling in AD tissue
Amyloid and C. pneumoniae immunoreactivity were
detected in sections of the AD frontal (Figure 3A, B)
and temporal cortices (Figure 3C, D). Amyloid immu-
noreactivity was present in dense core mature plaques
(brown color) using a rabbit anti-amyloid 1-42 antibody
(Sigma) (Figure 3A), and a mouse monoclonal anti-amy-
loid antibody (4G8, Signet) which also demonstrated
Figure 1 Chlamydia pneumoniae immunoreactivity in AD brain tissue.A l z h e i m e r ’s disease brain cerebral cortex immunolabeled with a
mouse anti-C. pneumoniae monoclonal antibody (Table 1, #5) demonstrates both intracellular and extracellular immunolabeling as indicated by
the magenta color. Panel A illustrates the temporal cortex labeled with no primary antibody and both anti- mouse HRP and anti-mouse AP
conjugated secondary antibodies reacted with both DAB and AP red. Panel B illustrates an extracellular labeling pattern and panels C and D
illustrate cellular labeling in the frontal cortex. Areas delineated by the boxes are higher magnification images of the immunoreactivity in panels
B-D. Size bar = 50 μm.
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Page 3 of 12intraneuronal amyloid labeling in the temporal region of
the AD brain (Figure 3C). Both the frontal and temporal
cortices demonstrated C. pneumoniae intra- and extra-
cellular immunoreactivity with multiple monoclonal
antibodies (Figure 3B, D; Table 1, #5, #3, respectively).
Both amyloid and chlamydial immunoreactivity were
visible at low magnification. Interestingly, although
C. pneumoniae was found in the frontal cortex in the
AD cases, we observed more consistent evidence of C.
pneumoniae in the temporal cortex. Further, Chlamydial
immunoreactivity occurred in apposition with amyloid
pathology in chlamydia positive areas. There was
a p p r o x i m a t e l y5 - 1 0 %o ft h ea r e ai m m u n o l a b e l e dw i t h
amyloid compared to 1-5% of the same area immunola-
beled for intracellular and extracellular chlamydia.
There appeared to be no consistent pattern to the area
or region in which the immunolabeling occured.
Furthermore, in the temporal cortex for 2 of 5 non-AD
cases, C. pneumoniae labeling was observed, although
less prominently as compared to the AD brains. These
non AD cases also demonstrated diffuse amyloid immu-
nopositivity (data not shown).
Association of C. pneumoniae labeling and Thioflavin S
staining
To further illustrate the relationship between amyloid
and chlamydia, temporal AD sections were labeled with
an anti-C. pneumoniae antibody (Table 1, #5) (red) and
then stained for Thioflavin S (yellow-green fluorescence
using the FITC filter ) on the same section. For this
dual procedure, optimal results were obtained when
immunohistochemistry (IHC) was performed prior to
Figure 2 Chlamydia pneumoniae immunoreactivity in hippocampus and entorhinal Cortex.D e t e c t i o no fC. pneumoniae antigen in the
Alzheimer’s disease hippocampus in panels A and B. Representative immunolabeling with mouse anti-C. pneumoniae monoclonal antibody
(Table 1, #5) shows immunopositivity in the dentate gyrus of the hippocampus. Immunolabeling is indicated by the magenta color and is
denoted by the arrows in panel A. Extracellular and intracellular C. pneumoniae immunolabeling in apparent large neurons is found within the
entorhinal cortex, panels C and D. Prominent labeling (magenta) denoted by the arrows in panels C and D, is easily distinguished from
intraneuronal lipofuscin (golden brown) denoted by the arrowheads (panel D). High magnification images of chlamydial labeling within different
cell types in the hippocampal region are illustrated in panel E (1, 8: neuroglia; 2: peri-vascular; 3, 4, 5, 6, 7, 9: neuronal). Note the apparent tangle
within the neuron in E9.Size bars: A, C, and D = 50 μm; B = 20 μm; E = 10 μm.
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images of the areas of interest were captured and then
overlaid or merged. This approach revealed the close
proximity of chlamydia with NFTs and NSPs, which are
hallmarks of Alzheimer’s disease pathology (Figure 4).
Pre-absorption of anti-C. pneumoniae antibodies with
Amyloid b 1-40 and 1-42 peptides
Upon detection of atypical extracellular chlamydia immu-
noreactivity, we questioned whether anti-chlamydia anti-
bodies could label extracellular deposits of amyloid. To
address this issue, we labeled several AD brain serial sec-
tions with separate anti-C. pneumoniae antibodies that
had been pre-absorbed with amyloid peptides. The immu-
noreactivity for C. pneumoniae was not depleted after
labeling with these pre-absorbed antibodies (Figure 5A-D).
Figure 5A demonstrated the representative extracellular
and intracellular immunoreactivity of a non- pre-absorbed
monoclonal anti-C. pneumoniae antibody (Table 1, #3) on
frontal AD tissue. Similar extracellular and intracellular
immunolabeling of C. pneumoniae antigen was obtained
with the antibody pre-absorbed against >10 molar excess
Sigma amyloid Ab1-40 peptide (Figure 5B) and with the
antibody pre-absorbed against >10 molar excess Sigma
amyloid Ab1-42 peptide (Figure 5C, D). Comparable
results were obtained with two other anti-C. pneumoniae
antibodies pre-absorbed in the same manner (Table 1, #1,
#2) (data not shown).
Discussion
Intracellular and extracellular C. pneumoniae immunor-
eactivity was observed in the entorhinal cortex, the
Figure 3 Amyloid and Chlamydia pneumoniae immunolabeling in AD tissue. Representative amyloid and C. pneumoniae immunolabeling
detected in frontal (A, B) and temporal (C, D) sections of an AD brain. For amyloid labeling (brown color), two different anti-amyloid antibodies
were used, (Sigma, panel A) and (Signet, panel C). Representative amyloid immunoreactivity, both extracellular plaques, including dense core
plaques (A), and intracellular labeling (C) are revealed at a low magnification in order to appreciate the level of amyloid pathology. Likewise,
C. pneumoniae immunoreactivity (magenta color) is evident at low magnification in both brain regions using two different monoclonal
antibodies (Table 1, #5 panel B), and (Table 1, #3 panel D). Size bar A, B = 50 μm; C, D = 100 μm.
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of the brain that typically demonstrate AD pathology.
Clear discrimination between chlamydia immunoreactiv-
ity and age-related lipofuscin accumulation within neu-
rons was demonstrated. Serial sections of brain tissue
displayed both amyloid pathology and the presence of
C. pneumoniae immunoreactivity. Thioflavin S staining
for fibrillar amyloid and specific antibody labeling for
C. pneumoniae revealed deposition of both when per-
formed on the same section. As some C. pneumoniae
labeling was extracellular, a more atypical pattern,
pre-absorption studies with Amyloid b 1-40 and 1-42
were performed. These studies revealed that C. pneumo-
niae antibodies were not cross-reacting with Ab. Collec-
tively, these data demonst r a t et h a te v i d e n c eo f
C. pneumoniae infection is present in brain tissues in
areas of amyloid pathology, thereby suggesting that an
interrelationship exists between these entities in the
pathogenesis of sporadic late-onset AD.
Immunolabeling for Chlamydia may be overlooked in
brain tissues, as it is different from what is observed in
cellular infections in vitro. In all AD samples analyzed
Figure 4 Dual Chlamydia pneumoniae labeling and Thioflavin S staining of the temporal cortex from an AD brain .Alzheimer’sd i s e a s e
temporal cortex is immunolabeled with a monoclonal anti-C. pneumoniae antibody (Table 1, #5) followed by staining with Thioflavin S on the
same tissue specimen. Panel A shows intracellular and extracellular C. pneumoniae immunoreactivity (magenta color). Using a FITC filter, panel B
shows both Thioflavin S positive intracellular labeling, presumably NFTs, and extracellular amyloid plaques (yellow fluorescence). Panel C shows
the light (panel A) (C. pneumoniae) image overlaid on the fluorescent (panel B) (Thioflavin S) image. Panel D shows merged light and
fluorescent images of another region of this temporal cortex illustrating merged chlamydia chromogen immunoreactivity and Thioflavin S
amyloid/tau fluorescence. Size bars = 50 μm.
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mydia immunoreactivity and atypical extracellular label-
ing were observed. Intracellular labeling demonstrated
punctate elementary bodies and membrane bound inclu-
sions similar to that of in vitro studies (see Figure 2E).
This specific labeling was differentiated from lipofuscin
by using red chromogens, either alkaline phosphatase
(AP)red or AP magenta, as the substrate to denote C.
pneumoniae immunoreactivity. Horseradish peroxidase
labeling with 3, 3′-Diaminobenzidine (DAB), a brown
chromogen, was not used as this labeling may be con-
fused with the golden brown lipofuscin found in neu-
rons of aged brains.
Two distinct extracellular patterns of chlamydia
immunoreactivity were observed: one, a punctate pattern
signifying the elementary body form of the bacteria,
which can be extruded from infected cells into the
surrounding milieu [31], and two, an amorphous foci
pattern most likely indicating secreted chlamydial fac-
tors such as lipopolysaccharide [30,31]. These patterns
in the cerebrum will require further study although
similar profiles of Chlamydia labeling in situ have been
demonstrated in a different organ [32]. Furthermore,
our data demonstrated that C. pneumoniae extracellular
immunoreactivity was not reflective of cross-reactivity
with extracellular Amyloid b 1-40 or 1-42. However,
C. pneumoniae extracellular organism and related anti-
gens may interact with extracellular proteins and lipids
in the brain. Although not always in direct overlap with
amyloid plaque deposits, chlamydial antigens may inter-
act with soluble oligomeric forms of amyloid, such as
ADDLs, that are less likely to be found in mature
Figure 5 Immunohistochemistry using an amyloid-pre-absorbed anti-Chlamydia pneumoniae antibody. Panels A-D illustrate anti-C.
pneumoniae immunoreactivity (red) in frontal AD tissue. The antibody for detection of C. pneumoniae is a mouse monoclonal C. pneumoniae
antibody (Table 1, #3). Panel A illustrates the extent of anti-C. pneumoniae immunoreactivity with the non-pre-absorbed antibody. Panel B
shows the extent of immunolabeling on the tissue when labeled with the 1-40 pre-absorbed antibody (pre-absorbed against >10 molar excess
Sigma amyloid Ab1-40 peptide). Panels C and D (higher power of panel C) show the extent of immunolabeling on the tissue when labeled with
the 1-42 pre-absorbed antibody (pre-absorbed against >10 molar excess Sigma amyloid Ab1-42 peptide). Size bar for panels A-C = 50 μm and
panel D = 20 μm.
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findings and their implications require further under-
standing of the possible relationship between amyloid
and chlamydia in the same cortical regions of the brain.
This relationship will vary with each individual AD
patient. Each AD patient has different levels of pathol-
ogy and may have corresponding variability in extent
and distribution of C. pneumoniae infection in the cere-
brum. Following further studies into this variability, the
relationship between pathology and infection can be
more thoroughly evaluated.
Although C. pneumoniae is principally a respiratory
pathogen, infection of the brain has been shown follow-
ing intranasal and lung infection [33,34]. In this regard,
monocytes infected with C. pneumoniae in the lungs
may spread the infection via the peripheral circulation
to the brain through the blood brain barrier or circum-
ventricular organs [22,23]. Alternatively, a more direct
and insidious route of infection may follow the olfactory
pathways. As such, the infection becomes established in
the olfactory nasal neuroepithelia, progresses to the
olfactory bulbs, and eventually infects brain structures
such as the entorhinal cortex and hippocampus. The
olfactory structures, the entorhinal cortex, and the
hippocampal formation are the most vulnerable and the
earliest regions affected in the onset of AD [35,36]. Our
current study highlights C. pneumoniae detection in the
frontal and temporal cortices, including the entorhinal
cortex and the hippocampal formation. Thus, infection
of these regions in the brain may have great impact on
the development of AD pathology.
Previous studies have demonstrated C. pneumoniae in
both human and animal olfactory bulbs [8,33,34]. In
both cell culture and animal studies, C. pneumoniae has
been shown to infect nasal neuroepithelial cells [34]. In
the animal studies, infection appeared to spread centri-
fugally from the vulnerable neuronal cells in the olfac-
tory bulb into the brain [33,34,37]. Further, Chlamydia
isolated from AD brains in a prior study was shown to
have more commonalities with Chlamydia respiratory
strains than with Chlamydia strains from atherosclerosis
with the suggestion that the organism itself may have a
tropism for specific cell types in the CNS [38]. Upon
consideration of these data and our current data, a
rationale for the selective vulnerability of specific brain
regions to infection and resultant pathology emerges.
Notably, histopathological amyloid plaques and tangles
are used to define the stage of AD, but the correlation
with the pathology of the disease and the clinical mani-
festations of the disease are not always clear [2]. Some
individuals who have massive pathology have little to no
symptoms. On the other hand, some symptomatic indi-
viduals may show little pathology upon post-mortem
histopathological examination. As such, there are many
variations in the amount and type of damage evident
in AD [1]. The variability of correlation between the
symptomology and histopathology suggests other events
and/or ingredients may be missing in the pathobiology
of AD.
The response in the brain to infection may determine
the extent of pathology and symptomatology that may
arise. In this regard, C. pneumoniae infection character-
istically promotes an inflammatory response whereby
cytokines such as IL-1b and TNF-a are secreted and
may initiate cellular damage [39]. These cytokine
responses to infection parallel similar responses to amy-
loid accumulation [40]. Additionally, another cellular
response to C. pneumoniae i n f e c t i o ni nc u l t u r ei st h e
production and processing of amyloid peptides. Labeling
of infected cells in culture for Amyloid b 1-42 often
reveals intracellular immunoreactivity at early post-
infection times (unpublished observations CJH, DMA,
CSL, BJB). Interestingly, our earlier study demonstrated
intracellular and extracellular amyloid deposits in the
brains of non-transgenic BALB/c mice following intra-
nasal C. pneumoniae infection [34]. Our current study
showed a similar relationship in which we demonstrated
both amyloid and chlamydia immunoreactivity in the
temporal cortex of the AD brain.
Further evaluation is required to specifically demon-
strate how amyloid and C. pneumoniae, both intracellu-
lar and extracellular, are interrelated. In addition, future
studies are required to further characterize the atypical
extracellular Chlamydial immunolabeling profiles.
Others have demonstrated evidence for an association of
infection and amyloid in AD [41]. HSV1 viral DNA was
shown to specifically associate with AD amyloid plaques
[41]. Previous hypotheses have even suggested that amy-
loid in the AD brain may act as an antiviral agent [42]
or an entrapping agent for infection [43]. Intriguingly, a
recent study suggests that amyloid has anti-microbial
properties, and may arise in response to brain infection
in AD [44]. As 2 of 5 non-AD cases in our current
study showed occasional chlamydia immunoreactivity
and diffuse amyloid deposition, future analysis must also
include mild cognitive impairment cases, as well as non-
AD cases, as infection may be a prodromal event leading
to eventual AD pathology.
Conclusions
The exact consequences of infection that correlate best
with the stage and subtype of Alzheimer’s disease
require ongoing investigation. This is true especially
with regard to the hallmarks of the disease such as amy-
loid plaques and tau tangles. Alzheimer’s disease is man-
ifest with multifactorial aspects of pathology and with
potentially multiple associated environmental factors,
including infectious agents [8,10-12]. Further, our
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the brain involved with olfaction are important to study
as infection in these regions, as well as in the olfactory
neuroepithelia and olfactory bulbs, may be a precursor
to the pathology associated with AD. Identification and
localization of infectious agents, such as Chlamydia
pneumoniae, in specifically vulnerable areas and cell
types in the brain is paramount. This determination
may be a missing link in the current strategy of associat-
ing symptomatology to disease pathogenesis in sporadic
late-onset Alzheimer’s disease.
Methods
Human Post-mortem Samples
Post-mortem tissue samples from various brain regions
(frontal and temporal cortices) of patients with and
without AD were obtained through Dr. William Hill of
the Medical College of Georgia (Augusta, GA), from the
MCP-Hahnemann School of Medicine Department of
Pathology, currently Drexel University College of Medi-
cine (Philadelphia, PA), and the Alzheimer’sR e s e a r c h
Center of the Health Partners Research Foundation at
Regions Hospital (St Paul, MN) under approved proto-
cols at each procurement site. Five AD and 5 non-AD
age-matched male and female archival brains were
examined. All cases were confirmed as AD or non-AD
by neuropathological examination at the source using
standard diagnostic criteria (NINDS/CERAD) [45].
Optimization of Immunohistochemistry
To detect chlamydia in the brain, IHC was performed on
serial sections from formalin-fixed, paraffin-embedded
Alzheimer brain tissue. Parallel IHC was performed using
antibodies for AD amyloid plaque pathology, specifically
anti-amyloid 1-42 antibodies. Amyloid plaques were best
visualized when antigen retrieval was not performed
whereas the optimal labeling for chlamydia antigens was
achieved following antigen retrieval. Optimum immunor-
eactivity occurred at 37°C in a humidified chamber for
both amyloid and chlamydial antigens. To visualize amy-
loid deposits, 3, 3′ Diaminobenzidine (DAB) (golden
brown color) was used. Red chromogens such as alkaline
phosphatase (AP) red and AP new magenta were found
to best visualize both intracellular and extracellular
C. pneumoniae, as nothing in a typical brain section
should appear red. For counterstaining, Mayer’s hema-
t o x y l i nw a sc h o s e na si to n l ys t a i n st h en u c l e u sl e a v i n g
the cytoplasm of the cell clear allowing easier visualiza-
tion of intracellular chlamydia EB and inclusion immuno-
labeling. Controls were used to rule out non-specific
labeling. Our controls included: no primary or secondary
antibodies, primary with no corresponding secondaries,
no primary but HRP conjugated secondary and/or AP
conjugated secondary alone and in combination, and
anti-human IgG primary with appropriate HRP and/or
AP secondaries alone and in combination, all of
which were reacted with appropriate substrates DAB
and/or AP red and/or AP magenta, alone and in combi-
nation. Controls for fluorescent work also included no
primary, secondary, or stain to allow for evaluation of
autofluorescence of the brain tissues.
Chlamydia pneumoniae Immunohistochemistry
Archival, paraffin-embedded, human brain tissues were
deparaffinized through xylenes and graded alcohols.
Antigen retrieval was performed in The Retriever
(Electron Microscopy Science, Fort Washington, PA)
according to manufacturer’s directions using 1 × Citra
Antigen retrieval buffer (BioGenex, San Ramen, CA).
The sections were rinsed with filtered water 3 × 5 min
and treated with Alkaline Phosphatase/Horseradish
Peroxidase Block (BioFX Laboratories, Owings Mills,
MD) for 30 min at room temperature (RT). The tissues
were rinsed with filtered water, PBS 3 × 5 min, and
blocked in 1% Fetal Bovine Serum (FBS)/PBS for
5 min at RT. Sections were incubated in a humidified
chamber with anti-chlamydia primary antibodies for
90 min at 37°C. Anti-chlamydial antibodies, genus
and species specific, were purchased from commercial
sources and used at dilutions shown in Table 1.
Following the incubation, the sections were rinsed with
PBS 3 × 5 min and blocked with 1% FBS/PBS block
for 5 min at RT. The sections were incubated in a
humidified chamber with app r o p r i a t ea n t i - m o u s eo r
anti-rabbit Alkaline Phosphatase conjugated secondary
antibody for 60 min at 37°C (BioFX Laboratories,
Owings Mills, MD or Zymed- Invitrogen Corporation,
Carlsbad, CA). After 3 × 5 min water rinses, the sec-
tions were reacted with BioFX AP-New Magenta IHC
Substrate (BioFX Laboratories- SurModics, Owings
Mills, MD) 40 min at RT or they were reacted with
AP red (Zymed- Invitrogen Corporation, Carlsbad, CA)
according to the manufacturer’sd i r e c t i o n s .T h es e c -
t i o n sw e r er i n s e dw i t hw a t e ra n dc o u n t e r s t a i n e dw i t h
Mayer’s hematoxylin (Electron Microscopy Science,
Fort Washington, PA). The slides were aqueous
mounted using Crystal Mount (Biomeda, Thermo
Fisher Scientific, Pittsburgh, PA) and then permanently
mounted using Permount (Thermo Fisher Scientific,
Pittsburgh, PA). Sections were viewed on a Nikon
Eclipse E800 or a Nikon Eclipse 90i microscope and
captured using: the spot RT (Diagnostic Instruments,
Starling Heights, MI) with the Image Pro Plus Phase 3
Imaging software (Media Cybernetics, Silver Spring,
MD), the Nikon DS-Fi1 camera using the NIS-Ele-
ments Advanced Research version 3.0 software (Nikon)
or the Nikon DS-Ri1 camera using the NIS-Elements
Advanced Research version 3.0 software (Nikon).
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Page 9 of 12Depending on the available tissue, the IHC was
performed on 2-3 serial sections for each antibody for
each section of the brain that was available. Out of the
battery of antibodies, 5 monoclonal and 1 polyclonal
antibodies were more routinely used (Table 1). In
order to be considered a positive sample, the sample
must have been positive by IHC with at least 2
C. pneumoniae species-specific monoclonal antibodies
i n2o ft h e3s e r i a ls e c t i o n so fe a c hb r a i ns e c t i o n .A l l
chlamydia antibodies used on the tissue sections were
also used on astrocyte, epithelial, monocyte, and/or
neuronal cell lines that were uninfected or that had
been infected with AR39 Chlamydia pneumoniae
(ATCC, Manassas, VA) as antibody specificity controls.
Amyloid Immunohistochemistry
Archival, paraffin-embedded, human brain tissues were
deparaffinized through xylenes and graded alcohols. The
sections were rinsed with filtered water and phosphate
buffered saline (PBS) 3 × 5 min. Endogenous peroxidase
was quenched using 3% H2O2 or Alkaline Phosphatase/
Horseradish Peroxidase Block (BioFX Laboratories,
Owings Mills, MD) for 30 min at RT. The tissues were
rinsed with sterile filtered water, PBS 3 × 5 min, and
blocked in 1% (FBS)/PBS for 5 min at RT. The primary
antibody, mouse anti-human b-Amyloid (4G8, Signet,
Covance, Cambridge, MA) or rabbit anti-Amyloid pep-
tide b cleavage site 42 (Sigma, St Louis, MO), were
incubated in a humidified chamber for 90 min at 37°C.
Following the incubation, the sections were rinsed with
PBS 3 × 5 min and blocked in 1% FBS/PBS block for 5
min at RT. The sections were incubated with anti-rabbit
horseradish peroxidase conjugated (HRP) secondary
antibody (Zymed, Invitrogen Corporation, Carlsbad, CA)
in a humidified chamber for 60 min at 37°C. After a
water rinse and PBS washes, 3 × 5 min, the sections
were reacted with 3, 3′-Diaminobenzidine (DAB) (Sigma
Aldrich, St Louis MI) for 10-20 min at RT. The sections
were rinsed with water and counterstained with Mayer’s
hematoxylin (Electron Microscopy Science, Fort
W a s h i n g t o n ,P A ) .S l i d e sw e r ed e h y d r a t e dt h r o u g h
graded alcohols and xylenes followed by cover slipping
using Permount (Thermo Fisher Scientific, Pittsburgh,
PA). Sections were viewed and captured as noted
previously.
Chlamydia pneumoniae antibody pre-absorption
Individual anti-chlamydia antibodies, mouse anti-
C. pneumoniae (Table 1, #2, #3, BioDesign, Meridian
Life Science, Inc., Saco, ME) or rabbit anti-chlamydia
antibody (Table 1, #1, BioDesign, Meridian Life Science,
Inc., Saco, ME), were mixed with >10 M excess of either
Amyloid b 1-40 or Amyloid b 1-42 peptide (Sigma,
St Louis, MO) in a batch method and allowed to
incubate overnight at 4°C. The supernatant of each pre-
absorbed antibody was then used for Chlamydia pneu-
moniae immunohistochemistry as described above with
the exception that secondary antibodies were conjugated
with HRP and reacted with DAB.
Dual Chlamydia pneumoniae Immunohistochemistry and
Thioflavin S staining
Slides immunolabeled for C. pneumoniae were stained
using a modified Thioflavin S protocol http://www-
medlib.med.utah.edu/WebPath/webpath.html[46].
In brief, following Chlamydia pneumoniae primary and
subsequent secondary incubations and AP-New
Magenta substrate development, slides were counter-
stained with Mayer’s hematoxylin and coversliped with
aqueous mount. Areas of chlamydia immunoreactivity
were identified by light microscopy. The aqueous mount
was then soaked off and the section were immersed in
1% Thioflavin S for 5 min, differentiated in 70% alcohol
for 5 min, and coverslipped with water. The sections
were kept wet by cover slipping with water as the inten-
sity of the Thioflavin S was diminished with use of Crys-
tal mount. Sections were viewed and captured while still
wet using a Nikon Eclipse E800 microscope and Nikon
DS-Ri1 camera. Light and fluorescent (under FITC
filter) images were captured and merged using the NIS-
Elements Advanced Research version 3.0 software
(Nikon).
Quantitative analysis
For determination of amyloid and chlamydia labeling
and the relationship between the two in the sections, we
evaluated the relationship with the following quantifica-
tion schemes.
For percentage of chlamydia pneumoniae immuno-
positiyity and percentage of type of immunopositivity,
we first qualitatively determined the types of label to be
counted: intracellular, extracellular or a combination of
the two. In representative frontal and temporal sections,
the total numbers of positives across a section were
counted and then the numbers of each category tallied
and the percentage of the total positive immunoreactiv-
ity was determined per total area across the section.
Analysis at 4, 10 and 40× magnification was performed
manually and utilizing the NIS-Elements Advanced
Research version 3.0 software (Nikon). Using the soft-
ware, the immunoreactivity was selected and the area or
cells were counted. A similar quantification scheme was
used in determining the relationship of the chlamydia
immunoreactivity relative to the amyloid immuno-
reactivity across a representative temporal region. In this
case, we again qualitatively determined the type of
immunoreactivity: intracellular, extracellular, or a mix-
ture of the two for amyloid and chlamydia. We then
Hammond et al. BMC Neuroscience 2010, 11:121
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Page 10 of 12determined the counts and areas of single label and then
the label of both in apposition to get an indication of
the relative relationships between the two antigens
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